The estimated Net Worth of George W. Lloyd is at least 76.8 百万$ dollars as of 2 June 2023. Mr Lloyd owns over 192,221 units of Royalty Pharma plc stock worth over 833,400$ and over the last 4 years he sold RPRX stock worth over 72,607,528$. In addition, he makes 3,395,000$ as Exec. VP of Investments & Gen. Counsel at Royalty Pharma plc.
Mr has made over 22 trades of the Royalty Pharma plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 192,221 units of RPRX stock worth 6,477,848$ on 2 June 2023.
The largest trade he's ever made was selling 252,500 units of Royalty Pharma plc stock on 4 June 2021 worth over 11,617,525$. On average, Mr trades about 64,600 units every 40 days since 2020. As of 2 June 2023 he still owns at least 30,000 units of Royalty Pharma plc stock.
You can see the complete history of Mr Lloyd stock trades at the bottom of the page.
George Wingate Lloyd is the Exec. VP of Investments & Gen. Counsel at Royalty Pharma plc.
As the Exec. VP of Investments & Gen. Counsel of Royalty Pharma plc, the total compensation of Mr Lloyd at Royalty Pharma plc is 3,395,000$. There are 2 executives at Royalty Pharma plc getting paid more, with Pablo Gerardo Legorreta having the highest compensation of 55,674,558$.
Mr Lloyd is 62, he's been the Exec. VP of Investments & Gen. Counsel of Royalty Pharma plc since . There are no older and 3 younger executives at Royalty Pharma plc.
George's mailing address filed with the SEC is C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK, NY, 10022.
Over the last 4 years, insiders at Royalty Pharma plc have traded over 863,995,127$ worth of Royalty Pharma plc stock and bought 5,330,350 units worth 152,553,456$ . The most active insiders traders include David C Hodgson、William E Ford、Capital Partners Gp, L.L.C..... On average, Royalty Pharma plc executives and independent directors trade stock every 13 days with the average trade being worth of 7,420,205$. The most recent stock trade was executed by Rory B Riggs on 2 January 2024, trading 470,000 units of RPRX stock currently worth 13,221,100$.
royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi
Royalty Pharma plc executives and other stock owners filed with the SEC include: